---
title: Reduce motor symptoms using synbiotic
nct_id: NCT05576818
phase: PHASE3
status: RECRUITING
sponsor: Tanta University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT05576818"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05576818"
last_fetched: "2026-05-10T14:07:47.745Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce motor symptoms using synbiotic

**Goal (in five words):** Reduce motor symptoms using synbiotic

**Official Title:** Clinical Study Evaluating the Efficacy and Safety of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's Disease

**Trial ID:** [NCT05576818](https://clinicaltrials.gov/study/NCT05576818)

## Key Facts

- **Phase:** PHASE3
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Tanta University
- **Target Enrollment:** 66 participants
- **Start Date:** 2022-06-30
- **Completion Date:** 2025-06
- **Conditions:** Parkinson's Disease
- **Interventions:** Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers
- **Intervention Types:** DRUG

## Summary For Families

The goal is to test whether adding a specific synbiotic can safely boost the effect of dopamine replacement and improve Parkinson's symptoms and related gut inflammation. The approach gives Lactobacillus acidophilus 10 billion CFU plus prebiotic fibers, the probiotic supplies beneficial bacteria and the prebiotic feeds them, with the idea of rebalancing the gut microbiome, reducing gut inflammation and oxidative stress, and possibly improving levodopa absorption or response. Eligible participants are adults 45 to 65 with Parkinson's on dopamine replacement and Hoehn and Yahr stages 1 to 4; people recently on antibiotics or other probiotics, with recent or planned GI surgery, probiotic allergy, enteral/IV nutrition, depression or psychosis, active inflammatory or oxidative-stress conditions, hyperthyroidism, smokers, or those taking antioxidant/anti-inflammatory drugs are excluded.

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 65 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Age between 45 and 65 years old
* Both sexes
* Patients with Parkinson's disease on dopamine replacement therapy
* Modified Hoehn and Yahr stage, MHY 1-4

Exclusion Criteria:

* Patients who are currently using or used antibiotics therapy in the preceding month
* Patients who are currently using or used other probiotic products in the preceding two weeks
* Patients scheduled to undergo GIT surgery or those underwent GIT surgery
* Patients with Known allergy to probiotics
* Patients receiving artificial enteral or intravenous nutrition
* Patients with depression and/or psychosis
* Patients taking antioxidant and/or anti-inflammatory medications
* Patients with Hyperthyroidism
* Patients with inflammatory condition and/or condition involving oxidative stress
* Smokers
* Modified Hoehn \& Yahr stage MHY 5
```

## Locations (1)

- Tanta University, Tanta, El Gharbia, Egypt _(30.7885, 31.0019)_
  - Mohamed E Ramadan — (CONTACT) — 201205280849 — mohamed_ehab@pharm.tanta.edu.eg

## Central Contacts

- Mohamed E Ramadan — (CONTACT) — 201205280849 — mohamed_ehab@pharm.tanta.edu.eg

---

*Canonical: https://parkinsonspathways.com/trial/NCT05576818*  
*HTML version: https://parkinsonspathways.com/trial/NCT05576818*  
*Source data: https://clinicaltrials.gov/study/NCT05576818*